RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.

Trial Details

NCT ID
NCT06389591
Phase
PHASE1
Sponsor
University of Florida
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)
  • RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
Locations (sample)
  • Gainesville, Florida, United States|29.65163,-82.32483

Key Eligibility Criteria

  • Age \>/= 18years
  • Histopathologically proven GBM using the 2021 WHO Classification of Tumors of the CNS (WHO CNS5).
  • Unequivocal evidence of tumor progression as documented by brain MRI scan per RANO criteria.
  • Tumor must have a primary supratentorial component at the time of disease progression.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →